|

Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction

RECRUITINGPhase 3Sponsored by National Institute of Cardiovascular Diseases, Pakistan
Actively Recruiting
PhasePhase 3
SponsorNational Institute of Cardiovascular Diseases, Pakistan
Started2024-12-02
Est. completion2025-11-30
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06742567

Summary

The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients aged 18-65 years
* Presenting with acute anterior STEMI
* Severe LV dysfunction (EF\<35%) with antero-apical akinesis, dyskinesis, or aneurysm
* WIHTOUT evidence of LV thrombus.

Exclusion Criteria:

* Patients with previous anterior myocardial infarction or LAD revascularization procedures
* Patients with cardiogenic shock
* Patients with LV thrombus
* Patients with advanced CKD (Cr \> 2 and those on hemodialysis)
* Recent ICH or major bleed requiring transfusion, low platelet counts \<100,000
* History of recent CVA ( within past three months)
* Patients with atrial fibrillation or other indications for chronic anticoagulation
* Pregnant patients and those with hematological disorders

Conditions4

Acute Myocardial Infarction of Anterior WallHeart DiseaseLeft Ventricular ThrombusProphylaxis

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.